GlassScriptPhysician profile
Matt Thomas Solverson
NPI 1437670288
$2,606.13
in general payments reported to CMS, 2019-2025
18 companies · $373 in 2025
The $373 reported for 2025 was more than what a typical Plastic Surgery Within The Head & Neck provider received nationally (typical 2025 total: $238).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $21.61 · 2021: $31.78 · 2023: $1,293 · 2024: $683 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,329 · Travel and Lodging: $1,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,329.08 |
| Travel and Lodging | $1,019.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,890.11 | 2023-2025 | Inspire |
| Intersect Ent, INC. | $140.61 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $88.39 | 2023-2024 | Dupixent, Libtayo |
| Medtronic, INC. | $82.47 | 2021-2024 | Propel |
| Merck Sharp & Dohme LLC | $59.29 | 2024 | Keytruda |
| Stryker Corporation | $53.00 | 2019-2024 | Na |
| Glaxosmithkline, LLC. | $38.19 | 2025 | Nucala |
| Acclarent, INC | $37.80 | 2019-2021 | |
| Smith+Nephew, INC. | $31.79 | 2024 | Tula |
| Cochlear Americas | $25.87 | 2019 | |
| Sun Pharmaceutical Industries INC. | $24.44 | 2025 | |
| Lilly USA, LLC | $22.68 | 2025 | Retevmo |
| Genzyme Corporation | $21.61 | 2020 | |
| Recordati_rare_diseases_inc. | $20.75 | 2024 | Sylvant |
| Novartis Pharmaceuticals Corporation | $18.99 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $18.45 | 2025 | Ultomiris |
| Acrotech Biopharma INC. | $17.13 | 2025 | Beleodaq |
| Iovance Biotherapeutics, INC. | $14.56 | 2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matt Solverson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.